Previous studies have historically shown that tacrolimus elevates levels of transforming growth factor-beta (TGF-β), thereby promoting cancer progression and metastatic disease in post-transplant hepatocellular carcinoma, human lung adenocarcinoma cells, and renal cell carcinoma [32]. The gene discussed is TGFB1; the disease is cancer.